D
F. Tamaddon, A. Khorram
Letter
Synlett
Funding Information
(16) Safaei-Ghomi, J.; Shahbazi-Alavi, H.; Sadeghzadeh, R.; Ziarati, A.
Res. Chem. Intermed. 2016, 42, 8143.
(17) Maleki, A.; Hajizadeh, Z.; Salehi, P. Sci. Rep. 2019, 9, 5552.
(18) Xu, H.; Li, L.; Wang, Z.; Xi, J.; Rong, L. Res. Chem. Intermed. 2018,
44, 3211.
We gratefully thank the Yazd University Research Council for financial
support.()
(19) MaGee, D. I.; Dabiri, M.; Salehi, P.; Koohshari, M.; Hajizadeh, Z.
ARKIVOC 2014, (iv), 204.
References and Notes
(20) Vanegas, S.; Rodríguez, D.; Ochoa-Puentes, C. ChemistrySelect
2019, 4, 3131.
(1) (a) Gawande, M. B.; Bonifácio, V. D.; Luque, R.; Branco, P. S.;
Varma, R. S. Chem. Soc. Rev. 2013, 42, 5522. (b) Kumaravel, K.;
Vasuki, G. Green Chem. 2009, 11, 1945. (c) Li, C.-J.; Anastas, P. T.
Chem. Soc. Rev. 2012, 41, 1413.
(2) (a) Narayan, S.; Muldoon, J.; Finn, M.; Fokin, V. V.; Kolb, H. C.;
Sharpless, K. B. Angew. Chem. Int. Ed. 2005, 44, 3275. (b) Butler,
R. N.; Coyne, A. G. Org. Biomol. Chem. 2016, 14, 9945. (c) Chanda,
A.; Fokin, V. V. Chem. Rev. 2009, 109, 725.
(3) Lipshutz, B. H.; Ghorai, S.; Cortes-Clerget, M. Chem. Eur. J. 2018,
24, 6672.
(4) (a) Katada, M.; Kitahara, K.; Iwasa, S.; Shibatomi, K. Synlett
2018, 29, 2408. (b) Cui, H.-L.; Shi, Y.; Deng, H.-Q.; Lei, J.-J.; Xu,
X.-J.; Tian, X.; Qiao, J.; Zhou, L. Synlett 2019, 30, 167. (c) Kalita, S.
J.; Deka, D. C. Synlett 2018, 29, 477.
(5) (a) Tian, Y.; Liu, Q.; Liu, Y.; Zhao, R.; Li, G.; Xu, F. Tetrahedron
Lett. 2018, 59, 1454. (b) Shaabani, A.; Hooshmand, S. E. Ultrason.
Sonochem. 2018, 40, 84. (c) Han, M.-Y.; Lin, J.; Li, W.; Luan, W.-
Y.; Mai, P.-L.; Zhang, Y. Green Chem. 2018, 20, 1228.
(6) Yang, J.; Mei, F.; Fu, S.; Gu, Y. Green Chem. 2018, 20, 1367.
(7) (a) Abu-Melha, S. Arch. Pharm (Weinheim, Ger.) 2013, 346, 912.
(b) Gudmundsson, K. S.; Johns, B. A.; Allen, S. H. Bioorg. Med.
Chem. Lett. 2008, 18, 1157.
(21) Tetrahydrodipyrazolopyridines; General Procedure
(NH4)2CO3 (2.0 mmol) was added to a stirred mixture of the
appropriate aldehyde (2.0 mmol), alkyl acetoacetate (4.0
mmol), and hydrazine hydrate (4.0 mmol) in H2O (1.0 mL), and
the mixture was stirred vigorously at r.t. for the appropriate
time (Table 3). The precipitated product was separated by
simple filtration.
4-(3,5-Dimethyl-1,4,7,8-tetrahydrodipyrazolo[3,4-b:4′,3′-
e]pyridin-4-yl)phenol (Table 3, Entry 3)
White solid; yield: 244.1 mg (92%); mp 267–269 °C (Lit.15 267–
268 °C). FTIR (KBr): 3234 (overlapped NH and OH stretching),
2935 (CH stretching), 1600 cm–1 (C=N stretching). 1H NMR (400
MHz, DMSO-d6): = 2.05 (s, 6 H, 2 CH3), 4.68 (s, 1 H, CH), 6.57
(d, J = 8 Hz, 2 H, Harom), 6.89 (d, J = 8 Hz, 2 H, ArH), 9.15 (s, OH),
11.52 (s, 3 H, 3 NH). 13C NMR (100 MHz, DMSO-d6): = 10.35,
31.76, 104.51, 114.45, 128.25, 133.36, 139.75, 155.05, 161.05.
3,5-Dimethyl-4-(4-tolyl)-1,4,7,8-tetrahydrodipyrazolo[3,4-
b:4′,3′-e]pyridine (Table 3, Entry 5)
White solid: 245.8 mg (88%); mp 244–246 °C (Lit.15 244–
246 °C). FTIR (KBr): 3170 (NH stretching), 2920 (CH stretching),
1610 (C=N stretching), 1520 (C=C aromatic), 1139 cm–1 (C–N
stretching). 1H NMR (400 MHz, DMSO-d6): = 2.1 (s, 6 H, 2 CH3),
2.20 (s, 3 H, p-CH3), 4.78 (s, 1 H, CH), 6.99–7.00 (m, 4 H, Harom),
11.25 (s, 3 H, 3 NH). 13C NMR (100 MHz, DMSO-d6): = 10.85,
20.98, 32.85, 104.85, 127.82, 128.83, 134.70, 140.20, 140.75,
161.50.
[4-(3,5-Dimethyl-1,4,7,8-tetrahydrodipyrazolo[3,4-b:4′,3′-
e]pyridin-4-yl)phenyl]dimethylamine (Table 3, Entry 9)
Yellow-orange solid: 299.1mg (97%); mp 250–252 °C. FTIR
(KBr): 3514, 3168 (NH stretching), 2942 (CH stretching), 1608
(C=N stretching), 1520 (C=C arom), 1139 cm–1 (C–N stretching).
1H NMR (400 MHz, DMSO-d6): = 2.26 (s, 6 H, 2 CH3), 2.91 (s, 6
H, 2 p-CH3), 4.9 (s, 1 H, CH), 6.75 (d, J = 8 Hz, 2 H, Harom), 7.3 (d,
J = 8 Hz, 2 H, Harom), 11.54 (s, 3 H, 3 NH).
(8) El-Borai, M. A.; Rizk, H. F.; Beltagy, D. M.; El-Deeb, I. Y. Eur. J.
Med. Chem. 2013, 66, 415.
(9) (a) Souza, D. M.; Müller, T. J. J. Chem. Soc. Rev. 2007, 36, 1095.
(b) Isambert, N.; Lavilla, R. Chem. Eur. J. 2008, 14, 8444. (c) Gu,
Y.; De Sousa, R.; Frapper, G.; Bachmann, C.; Barrault, J.; Jérôme,
F. Green Chem. 2009, 11, 1968. (d) Müller, T. J. J. Chem. Hetero-
cycl. Comp. 2017, 53, 381.
(10) (a) Pirrung, M. C.; Sarma, K. D. J. Am. Chem. Soc. 2004, 126, 444.
(b) Kumaravel, K.; Vasuki, G. Curr. Org. Chem. 2009, 13, 1820.
(c) Wu, J.; Bishop, L.; Guo, J.; Guo, Z. Synlett 2019, 30, 348.
(11) Tamaddon, F.; Razmi, Z.; Jafari, A. A. Tetrahedron Lett. 2010, 51,
1187.
(12) (a) Tamaddon, F.; Ghazi, S. Catal. Commun. 2015, 72, 63.
(b) Tamaddon, F.; Alizadeh, M. Tetrahedron Lett. 2014, 55, 3588.
(13) (a) Tamaddon, F.; Tadayonfar, S. J. Mol. Liq. 2019, 280, 71.
(b) Tamaddon, F.; Tadayonfar, S. J. Mol. Liq. 2019, 283, 51.
(14) (a) Lehninger, A. L.; Cox, M. M.; Nelson, D. L. Lehninger Principles
of Biochemistry, 4th ed; W. H. Freeman: New York, 2005, 190.
(b) Khoshneviszadeh, M.; Edraki, N.; Javidnia, K.; Alborzi, A.;
Pourabbas, B.; Mardaneh, J.; Miri, R. Bioorg. Med. Chem. 2009,
17, 1579. (c) Keri, R. S.; Patil, S. A. Biomed. Pharmacother. 2014,
68, 1161. (d) Ghosh, P.; Mukherjee, P.; Das, A. R. RSC Adv. 2013,
3, 8220.
3,5-Dimethyl-4-(4-nitrophenyl)-1,4,7,8-tetrahydrodipyra-
zolo[3,4-b:4′,3′-e]pyridine (Table 3, Entry 11)
Cream solid: 291.7 mg (94%); mp 333–335 °C (Lit.15 >300 °C).
FTIR (KBr): 3250 (NH stretching), 2985 (CH stretching), 1605
(C=N stretching), 1489 (overlapped asymm stretching NO2 with
C=C arom), 1352 (NO2 symm stretching), 753 cm–1 (out-of-plane
bending C–H, para-substituted). 1H NMR (400 MHz, DMSO-d6):
= 2.1 (s, 6 H, 2 CH3), 4.95 (s, 1 H, CH), 7.35 (d, J = 8 Hz, 2 H,
H
arom), 8.1 (d, J = 8 Hz, 2 H, Harom), 11.20 (s, 3 H, 3 NH). 13C NMR
(100 MHz, DMSO-d6): = 10.70, 33.40, 103.60, 123.40, 129.20,
140.20, 146.1, 152.25, 161.35.
(15) (a) Zhao, K.; Lei, M.; Ma, L.; Hu, L. Monatsh. Chem. 2011, 142,
1169. (b) Shabalala, N. G.; Pagadala, R.; Jonnalagadda, S. B. Ultra-
son. Sonochem. 2015, 27, 423.
© 2020. Thieme. All rights reserved. Synlett 2020, 31, A–D